The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Richard Perrin, Anne Fagan, Hideaki Bujo
Project Title: Amendment to T1207 – Effects of APOE and AD on CSF sLR11
Date: December 21, 2021 at 5:02 pm
Request ID: T1207-B
Aim 1: Evaluate effect of APOE genotype on sLR11 levels in CSF
Aim 2: Evaluate effect of very early AD pathology on sLR11 levels in CSF
Aim 3:
Aim 4:
Investigator: Jennifer Smith
Project Title: Optimization and Validation of a Cell-based Assay for Blood-Based Diagnosis of Alzheimer�s Disease
Date: December 21, 2021 at 5:02 pm
Request ID: T1602
Aim 1: To test the performance of a recently developed indicator cell assay platform (iCAP) for blood-based diagnostics of AD. We propose to use 75 ADRC plasma samples to train and test iCAP-based classifiers to distinguish AD at pre-symptomatic and early stage of progression from normal controls.
Aim 2: To optimize the disease specificity of the AD iCAP. We propose to use 65 ADRC plasma samples to test and optimize the iCAP AD classifier�s ability to discriminate AD from other dementias such as lewy body dementia, frontotemporal dementia and vascular dementia.
Aim 3: To validate the final classifier with independent samples. We propose to use 125 ADRC plasma samples for blind independent testing of the classifiers. The final goal is a blood based iCAP for detection of presymptomatic and early AD with > 90% accuracy and specificity for AD over other dementias.
Aim 4: If only a fraction of the samples are available from ADRC, the project can be done using some samples from another source. In addition, as the aims are sequential, not all samples are required at once; we are willing to apply for approval in stages, contingent on meeting milestones for each aim.
Investigator: Sally Temple
Project Title: iPSC Line Generation to Develop the Tau Consortium Collection
Date: December 21, 2021 at 5:02 pm
Request ID: T1506
Aim 1: To generate iPSC from MAPT mutation carriers and related non-carriers
Aim 2:
Aim 3:
Aim 4:
Investigator: Christoph Laske
Project Title: Inflammatory profiling in plasma and cerebrospinal fluid in amyloid positive vs. amyloid negative cognitively normal elderly individuals
Date: December 21, 2021 at 5:02 pm
Request ID: T1507
Aim 1: To compare systemic and CNS inflammatory biomarkers between amyloid positive (preclinical AD) vs. amyloid negative cognitively normal elderly individuals
Aim 2: To determine the association between systemic & CNS inflammatory biomarkers & clinical parameters (age, gender, education), biochemical biomarkers (CSF levels of Abeta 1-42, Tau & pTau181) & neuro-imaging biomarkers (cortical PiB-PET) in amyloid positive vs. negative cognitively normal individuals
Aim 3:
Aim 4:
Investigator: NK Robakis
Project Title: PS1 Regulates Processing and Signaling of EphrinB/EphB
Date: December 21, 2021 at 5:02 pm
Request ID: T1508
Aim 1: Effects of PS1 FAD mutants on neuronal survival compolexes formed between tyrosine kinase receptors (such as EphB and Trk), PS1 and NR1 compared to normal controls.
Aim 2: Effects of PS1 FAD mutations on brain miR-212 and target protein PED/PEA15 compared to cognitively normal controls.
Aim 3:
Aim 4:
Investigator: Feng Lin
Project Title: New biomarkers for Alzheimer’s Disease
Date: December 21, 2021 at 5:02 pm
Request ID: T1608
Aim 1: We will analyze CSF samples from control and Alzheimer’s Disease patients to identify potential new biomarkers for future better dignosis of Alzheimer’s Disease
Aim 2:
Aim 3:
Aim 4:
Investigator: Anne Fagan
Project Title: Roche Elecsys automated CSF assay for Ab42, tau and ptau181
Date: December 21, 2021 at 5:02 pm
Request ID: T1606
Aim 1: Evaluate the analytical performance of the automated Roche Elecsys assay for CSF Ab42, tau and ptau181
Aim 2: Evaluate the clinical performance of the automated Roche Elecsys assay for CSF Ab42, tau and ptau181
Aim 3:
Aim 4:
Investigator: Anne Fagan
Project Title: Lumipulse Automated CSF Assay for Ab42 and tau
Date: December 21, 2021 at 5:02 pm
Request ID: T1605
Aim 1: To test Lumipulse CSF Ab42 and tau methodologic assay performance
Aim 2: To compare CSF biomarker profiles between African Americans and European Americans
Aim 3: To evaluate the correspondence between Lumipulse Ab42 and cortical amylioid load defined by PIB PET
Aim 4:
Investigator: Tammie L.S. Benzinger
Project Title: quantification of neuroinflammation and neurodegeneration in AD using DBSI
Date: December 21, 2021 at 5:02 pm
Request ID: T1604
Aim 1: Validate DBSI as a biomarker of neuroinflammation in AD
Aim 2: Validate DBSI as neurodegeneration markers in AD
Aim 3:
Aim 4:
Investigator: Dr. Venkata Mattay
Project Title: Identifying molecular mechanisms underlying resilience to the neuropathological hallmarks of Late-onset Alzheimer�s disease
Date: December 21, 2021 at 5:02 pm
Request ID: T1603
Aim 1: Determine cognitive resilience relevant biological pathways significantly enriched with genes (whole transcript, exon and exon junctions) that are differentially expressed between ADPC and LOAD patients
Aim 2: Explore an epigenetic basis for resilience factors by identifying differentially methylated genetic regions (DMRs) at CpGs between LOAD and ADPC brains
Aim 3:
Aim 4: